View in EDS

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.

Saved in:
Bibliographic Details
Title: A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Authors: Lopez JS; Drug Development Unit at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK. Electronic address: juanita.lopez@icr.ac.uk., Haefliger S; Inselspital, Bern University Hospital, University of Bern, Department of Medical Oncology, Bern, Switzerland., Plummer R; Newcastle University and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK., Clement PM; UZ Leuven - Department of Oncology, Leuven Cancer Institute - KU Leuven, Leuven, Belgium., Jeffry Evans TR; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Läubli H; Department of Oncology, University Hospital Basel, Basel, Switzerland., Roth P; Department of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland., Kristeleit R; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Brazil L; Guy's Hospital, Cancer Centre, London, UK., Tabatabai G; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls Uninversity Tübingen, Tübingen, Germany., Wick A; Neurology Department, University Clinic Universitätsklinikum, Heidelberg, Germany., Wunderlich B; Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany., Beebe K; GeneCentric Therapeutics Inc., Durham, NC, USA., Eisner JR; GeneCentric Therapeutics Inc., Durham, NC, USA., Lane H; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland., Engelhardt M; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland., Kaindl T; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland. Electronic address: thomas.kaindl@basilea.com., Hau P; Wilhelm Sander NeuroOncology Unit and Department of Neurology - Neurooncology, University Hospital Regensburg, Regensburg, Germany., Hundsberger T; Department of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, Sankt Gallen, Switzerland., Steinbach J; Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Jun 17; Vol. 6 (6), pp. 102165.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40532659
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lopez+JS%22">Lopez JS</searchLink>; Drug Development Unit at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK. Electronic address: juanita.lopez@icr.ac.uk.<br /><searchLink fieldCode="AU" term="%22Haefliger+S%22">Haefliger S</searchLink>; Inselspital, Bern University Hospital, University of Bern, Department of Medical Oncology, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Plummer+R%22">Plummer R</searchLink>; Newcastle University and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Clement+PM%22">Clement PM</searchLink>; UZ Leuven - Department of Oncology, Leuven Cancer Institute - KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Jeffry+Evans+TR%22">Jeffry Evans TR</searchLink>; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Läubli+H%22">Läubli H</searchLink>; Department of Oncology, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Roth+P%22">Roth P</searchLink>; Department of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kristeleit+R%22">Kristeleit R</searchLink>; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Brazil+L%22">Brazil L</searchLink>; Guy's Hospital, Cancer Centre, London, UK.<br /><searchLink fieldCode="AU" term="%22Tabatabai+G%22">Tabatabai G</searchLink>; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls Uninversity Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Wick+A%22">Wick A</searchLink>; Neurology Department, University Clinic Universitätsklinikum, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Wunderlich+B%22">Wunderlich B</searchLink>; Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany.<br /><searchLink fieldCode="AU" term="%22Beebe+K%22">Beebe K</searchLink>; GeneCentric Therapeutics Inc., Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Eisner+JR%22">Eisner JR</searchLink>; GeneCentric Therapeutics Inc., Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Lane+H%22">Lane H</searchLink>; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Engelhardt+M%22">Engelhardt M</searchLink>; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kaindl+T%22">Kaindl T</searchLink>; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland. Electronic address: thomas.kaindl@basilea.com.<br /><searchLink fieldCode="AU" term="%22Hau+P%22">Hau P</searchLink>; Wilhelm Sander NeuroOncology Unit and Department of Neurology - Neurooncology, University Hospital Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Hundsberger+T%22">Hundsberger T</searchLink>; Department of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, Sankt Gallen, Switzerland.<br /><searchLink fieldCode="AU" term="%22Steinbach+J%22">Steinbach J</searchLink>; Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101766894%22">Cell reports. Medicine</searchLink> [Cell Rep Med] 2025 Jun 17; Vol. 6 (6), pp. 102165.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101766894 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3791 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663791%22">26663791 </searchLink><i>NLM ISO Abbreviation: </i>Cell Rep Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40532659
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xcrm.2025.102165
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102165
    Titles:
      – TitleFull: A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lopez JS
      – PersonEntity:
          Name:
            NameFull: Haefliger S
      – PersonEntity:
          Name:
            NameFull: Plummer R
      – PersonEntity:
          Name:
            NameFull: Clement PM
      – PersonEntity:
          Name:
            NameFull: Jeffry Evans TR
      – PersonEntity:
          Name:
            NameFull: Läubli H
      – PersonEntity:
          Name:
            NameFull: Roth P
      – PersonEntity:
          Name:
            NameFull: Kristeleit R
      – PersonEntity:
          Name:
            NameFull: Brazil L
      – PersonEntity:
          Name:
            NameFull: Tabatabai G
      – PersonEntity:
          Name:
            NameFull: Wick A
      – PersonEntity:
          Name:
            NameFull: Wunderlich B
      – PersonEntity:
          Name:
            NameFull: Beebe K
      – PersonEntity:
          Name:
            NameFull: Eisner JR
      – PersonEntity:
          Name:
            NameFull: Lane H
      – PersonEntity:
          Name:
            NameFull: Engelhardt M
      – PersonEntity:
          Name:
            NameFull: Kaindl T
      – PersonEntity:
          Name:
            NameFull: Hau P
      – PersonEntity:
          Name:
            NameFull: Hundsberger T
      – PersonEntity:
          Name:
            NameFull: Steinbach J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 06
              Text: 2025 Jun 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3791
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Cell reports. Medicine
              Type: main
ResultId 1